Sanofi to acquire Ablynx for €3.9bn
Sanofi to buy Bioverativ for $11.6bn
France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, Zentiva, mergers & acquisitions, generics, Advent International, healthcare, M&A, pipeline, sales